| Attribute | Detail | Source / Year |
|---|---|---|
| Legal name | MERCK Kommanditgesellschaft auf Aktien | AR 2025 |
| Common name | Merck KGaA, Darmstadt, Germany | AR 2025 |
| US/Canada trade names | MilliporeSigma, EMD Serono, EMD Electronics | AR 2025 |
| Former names / predecessor forms | Engel-Apotheke (pharmacy, 1668); E. Merck (family partnership, pre-1995); converted to KGaA with IPO in 1995 | Company history |
| Founded | 1668 (Friedrich Jacob Merck acquires the Engel-Apotheke, Darmstadt) | AR 2025 |
| Legal form | Kommanditgesellschaft auf Aktien (partnership limited by shares) | AR 2025 |
| Incorporation jurisdiction | Germany (commercial register, Darmstadt) | AR 2025 |
| Ultimate parent / controlling holder | E. Merck KG, Darmstadt (founding family; 70.274% of total capital as general partner) | AR 2025 |
| Free float | 29.726% of total capital; 129.2 million shares | AR 2025 |
| Theoretical total shares (for EPS/market cap) | 434.8 million | AR 2025 |
| Headquarters | Frankfurter Straße 250, 64293 Darmstadt, Germany | Q1 2026 Financial Statement |
| Primary listing | Frankfurt Stock Exchange (Xetra), regulated market; DAX 40 member | AR 2025 |
| Ticker | MRK (Xetra); Bloomberg MRK GY; Reuters MRCG; Dow Jones MRK.DE | Q2 2026 press release |
| ISIN / WKN | DE0006599905 / 659990 | Q1 2026 Financial Statement |
| US OTC instruments | MKKGY (ADR, ISIN US5893392093, i.e. CUSIP 589339209); MKGAF (ordinary shares, OTC) | Market data providers |
| CUSIP for ordinary shares | Not applicable (German ISIN-only security) | — |
| Fiscal year end | 31 December | AR 2025 |
| Employees (31 Dec 2025) | 62,461 | AR 2025 |
| Employees (30 Jun 2026) | 62,136 | Q2 2026 press release |
| Countries with operations (2025) | 65 | AR 2025 |
| Auditor | Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Munich (elected by AGM on 24 April 2026 as auditor and Group auditor for FY2026; Deloitte also signed recent audit opinions — FY2025 auditor identity should be confirmed in the AR 2025 Independent Auditor's Report) | AGM 2026 convening notice |
| Market capitalisation (31 Dec 2025) | EUR 53,304 million (at EUR 122.60, 434.8m theoretical shares) | AR 2025 |
| Market capitalisation (latest verified) | ~EUR 57.2–57.7 billion at EUR 131.65 (Xetra close, 10 September 2026) | Market data (ftd.de); derived |
| Credit ratings | Moody's A3 (stable), S&P A (stable), confirmed November 2025 | AR 2025 |
| Websites | emdgroup.com (US/Canada); merckgroup.com (rest of world) | Company |
The entity profiled is MERCK Kommanditgesellschaft auf Aktien ("Merck KGaA, Darmstadt, Germany"), the German science and technology group headquartered in Darmstadt. It is a listed public company (DAX 40 constituent), which matches the "Public company" type supplied. It must not be confused with Merck & Co., Inc. (Rahway, New Jersey; "MSD" outside North America), which has been a separate, unrelated company since 1917. In the United States and Canada, Merck KGaA operates as MilliporeSigma (Life Science), EMD Serono (Healthcare) and EMD Electronics (Electronics); the corporate US-facing website is emdgroup.com.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Employees at 31 Dec (number) | 60334 | 64232 | 62908 | 62557 | 62461 |
Source: AR 2025, Business Development 2021–2025. Headcount at 30 June 2026 was 62,136 (Q2 2026 press release). The three-year trend (FY2023–FY2025) shows a gradual decline of ~0.7% cumulatively, reflecting the Surface Solutions divestment (July 2025) and efficiency measures, partially offset by the SpringWorks acquisition (July 2025). Around 6,500 employees work in R&D and related functions (AR 2025).
Merck KGaA is a 358-year-old, family-controlled, diversified science and technology group generating EUR 21.1 billion of net sales (FY2025) across three complementary business sectors: Life Science (42% of sales; a top-three global supplier of research tools, bioprocessing consumables and testing services, known in North America as MilliporeSigma), Healthcare (41%; a specialty pharmaceutical company with established franchises in oncology, multiple sclerosis, fertility and cardiometabolic care plus a new rare-tumour franchise acquired via SpringWorks), and Electronics (17%; a now pure-play semiconductor and optronics materials, equipment and metrology supplier exposed to AI-driven advanced nodes). The group operates at a ~29% EBITDA pre margin with net financial debt of ~1.4x EBITDA pre. Its investment case rests on three growth drivers — Process Solutions, Rare Diseases and Semiconductor Solutions — which management expects to generate up to 80% of medium-term growth, now being reinforced by the pending US$11.3 billion Bio-Techne acquisition.
---
### Company's own description (paraphrased from AR 2025)
The company describes itself as a science and technology company guided by the vision "Sparking Discovery, Elevating Humanity," working across Life Science, Healthcare and Electronics to create value for customers and patients. The founding family, now in its 13th generation, remains majority owner through the KGaA structure. Financial reporting presents three business sectors plus Corporate and Other, and five regions (Europe, North America, Asia-Pacific, Latin America, Middle East and Africa). The company's own boilerplate (2026 press releases) characterises its activity as accelerating drug development and manufacturing, discovering treatments for challenging diseases, and enabling "the intelligence of devices."
### Independent characterisation
Merck KGaA is best understood as a conglomerate of three high-margin specialty businesses with distinct economic cycles:
1. **Life Science** is a consumables-heavy, recurring-revenue tools franchise. Roughly 42% of sector sales (Process Solutions) are "embedded" in customers' validated biomanufacturing processes (filters, chromatography resins, single-use assemblies, cell culture media, excipients), creating high switching costs because regulatory re-validation is required to change suppliers. The research catalogue business (legacy Sigma-Aldrich; now Discovery Solutions) is a broad, transactional, e-commerce-led reagent business with more than 300,000 products. Services (testing, CDMO for ADCs/viral vectors/HPAPIs) are smaller and lumpier.
2. **Healthcare** is a mid-sized specialty pharma business whose cash generation rests disproportionately on mature, off-patent or near-off-patent brands (Glucophage, Concor, Euthyrox, Erbitux, Rebif, Gonal-f) and on Mavenclad, which began losing US exclusivity in 2026. The SpringWorks acquisition (July 2025) created a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly, pimicotinib) intended to offset these erosions. Historically, internal R&D productivity has been weak (late-stage failures of evobrutinib and xevinapant in 2023–2024).
3. **Electronics** is a materials-and-process-solutions supplier to semiconductor fabs (logic, memory, advanced packaging) and display panel makers. Following the Versum Materials (2019) and AZ Electronic Materials (2014) acquisitions and the 2025 divestment of Surface Solutions (pigments), it is positioned as a pure-play electronics business with 72% of sector sales in Asia-Pacific.
### Revenue model mix
| Revenue model | Where it sits | Characterisation | Disclosure status |
|---|---|---|---|
| Product sales — consumables/reagents | Life Science (Process, Discovery, Advanced Solutions) | Recurring, volume-driven; process-embedded in GMP manufacturing | Segment-level only |
| Product sales — instruments/equipment | Life Science (lab water, automation), Electronics (DS&S delivery systems, Unity-SC metrology tools) | Capex-cyclical, project-driven | Not separately disclosed |
| Product sales — prescription pharmaceuticals | Healthcare | Patent/brand-driven; exposed to pricing, tenders, generics | Product-level sales disclosed |
| Product sales — specialty electronic materials | Electronics (Thin Films, Formulations, Specialty Gases, display materials) | Recurring, wafer-start driven; qualified per node | BU-level only |
| Services | Life Science Services/Advanced Solutions (contract testing, CDMO), Electronics (MEGASYS gas & chemical services) | Contracted, multi-year in part (e.g. Genetix five-year testing agreement, May 2026) | Not separately disclosed |
| Licensing/collaboration income | Healthcare (alliances; collaboration income included in net sales by definition) | Irregular | Not separately disclosed |
| Subscription/software | Life Science (Synthia, AIDDISON, ChemisTwin, Athinia/Syntropy data platforms) | Nascent | Not publicly disclosed |
The company does not disclose a product/service/subscription/licensing percentage split. Analyst view: product sales (consumables, materials and medicines) constitute the overwhelming majority (>90%) of group revenue; this is an estimate and is flagged as such.
### Value-chain position and customers
| Sector | Value-chain position | Customer types | End-markets |
|---|---|---|---|
| Life Science | Upstream supplier of tools, raw materials and services to drug discovery, development, manufacturing and QC | Academic/government labs, biotech, pharma, CDMOs, diagnostics, industrial/applied labs | Biopharma (mAbs, ADCs, cell & gene therapy, vaccines), academic research, diagnostics, food/environmental testing |
| Healthcare | Integrated discovery-to-commercialisation specialty pharma | Prescribers, hospitals, payers, governments, IVF clinics, distributors | Oncology, neurology & immunology, fertility, cardiometabolic/endocrinology, rare tumours |
| Electronics | Tier-1 materials, delivery systems, metrology/inspection supplier to fabs and panel makers | Logic foundries, memory makers, OSATs, display panel makers | AI/HPC chips, memory, advanced packaging, displays, AR/VR optics |
Regional mix of sector sales (AR 2025): Life Science 71% Europe + North America, 28% Asia-Pacific + Latin America; Healthcare 54% Europe + North America, 39% Asia-Pacific + Latin America; Electronics 72% Asia-Pacific, 26% Europe + North America.